Incannex Healthcare Limited (IXHL)
NASDAQ: IXHL · IEX Real-Time Price · USD
2.250
-0.100 (-4.26%)
At close: Jul 19, 2024, 4:00 PM
2.290
+0.040 (1.78%)
Pre-market: Jul 22, 2024, 5:50 AM EDT
Incannex Healthcare Employees
Incannex Healthcare had 10 employees as of June 30, 2023. The number of employees increased by 5 or 100.00% compared to the previous year.
Employees
10
Change (1Y)
5
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
39.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2023 | 10 | 5 | 100.00% |
| Jun 30, 2022 | 5 | 1 | 25.00% |
| Jun 30, 2021 | 4 | 0 | - |
| Jun 30, 2020 | 4 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Nortech Systems | 775 |
| Co-Diagnostics | 155 |
| Owlet | 76 |
| electroCore | 68 |
| Movano | 30 |
| Dyadic International | 7 |
| ProMIS Neurosciences | 7 |
| Bright Green | 5 |
IXHL News
- 7 weeks ago - Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea - GlobeNewsWire
- 2 months ago - Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder - GlobeNewsWire
- 2 months ago - Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD) - Newsfile Corp
- 5 months ago - Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation - GlobeNewsWire
- 6 months ago - Clarion Clinics Open for Psychedelic-Assisted Treatments - GlobeNewsWire
- 6 months ago - Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis - GlobeNewsWire
- 6 months ago - Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences - GlobeNewsWire
- 6 months ago - Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea - GlobeNewsWire